

**NATIONAL PATIENT GROUP DIRECTION FOR URGENT PROVISION OF REPEAT
MEDICINES, APPLIANCES AND ACBS PRODUCTS.**

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS.**

**IT IS THE RESPONSIBILITY OF THE INDIVIDUAL TO ENSURE THEY ARE USING THE
MOST UP TO DATE PGD**

1. Authorisation

Developed on behalf of NHS Scotland by NHS 24 by:

Physician Dr George Crooks Signature _____

Pharmacist Dr John McAnaw Signature _____

NHS Scotland
Representative John Turner Signature _____

Authorised for use on behalf of _____ Health Board by

Medical Director _____ Signature _____

Senior
Pharmacist _____ Signature _____

Clinical
Governance
Lead _____ Signature _____

Date Approved _____

Effective from _____ Expires _____

2. Management of the Patient Group Direction (PGD)

This PGD must be read, agreed to and signed by all pharmacists involved in its use. The original signed copy should be held by the Health Board.

3. Application

This PGD covers the urgent provision of current repeat NHS prescribed medicines, appliances and ACBS products to NHS patients by pharmacists when the patient's prescriber is unavailable; the surgery is closed or if an out-of-hours system is in operation.

4. Clinical Condition

Situation	The provision from a pharmacy with an NHS contract of repeat NHS prescribed medicines, appliances and ACBS products required when the patient is unable to obtain a prescription for further supplies in the normal way for the clinical conditions listed in schedules 1 to 15 of this PGD.
Inclusion Criteria	Medicines and/or appliances and/or ACBS products requested by patient and are currently being prescribed by patient's prescriber. The requirement to interview the patient directly prior to a supply being made will be removed in the case of an announcement of a pandemic or imminent pandemic (WHO level 6).
	Medicines and/or appliances and/or ACBS products are allowed on NHS prescription.
	Surgery is closed and/or prescriber unavailable.
	Patient is registered (or temporarily) with a medical practice in Scotland.
Exclusion Criteria	Patient agrees to relevant clinical information being provided to the pharmacist.
	Provision is not urgent.
	Patient's medicines and/or appliances and/or ACBS products are not on repeat prescription.
	Medicines and/or appliances and/or ACBS products are not allowed on NHS prescription.
	No agreement to share relevant clinical information.
	Urgent provision for the medicines and/or appliances and/or ACBS products requested at last prescribing cycle. Patient's clinical condition significantly changed.
Action if Excluded	Pharmacist's judgement to provide supply under existing emergency supply regulations.

Referral to Prescriber	Significant change in clinical condition.
	Any relevant reason by pharmacist.

5. Description of Treatment

Medicine	All medicines and/or appliances and/or ACBS products required and listed in BNF and BNFC described in the schedules to this PGD.
Legal Status	As described in the BNF or BNFC.
Dosage Form and Strength	As normally prescribed by the patient's prescriber. or Variation of product brand and/or dosage form and/or strength may be substituted when usual product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent.
Dose	As normally prescribed by the patient's prescriber or if not known as recommended by the BNF or BNFC.
Exceptions	As listed in the Annexes to this PGD.
Duration of Supply	One prescribing cycle i.e. quantity and duration normally prescribed to the patient or up to one months supply if not known.
Patient Information	Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet. Provision of any other relevant information as judged by the pharmacist operating under this PGD.
Documentation	The pharmacist will complete a CP(US) in accordance with the requirements contained in the guidance to this PGD.
Supply	The supply of medicine and/or appliances and/or ACBS products should comply with the requirement for labelling and be in an appropriate container or packaging.
Follow-up	Ensure that the patient's prescriber is notified and that all records are complete and CP(US) is forwarded to NHS NSS.
Adverse reactions	As described in BNF or BNFC.
Patient Charges	Normal charge equivalent to that applied to an NHS prescribed item and current NHS exemptions are applicable.

Record/Audit Trail

The CP(US) should be forwarded to NHS NSS for onward processing.

A record of the transaction i.e. a fax or photocopy of the CP(US) should be forwarded to the patient's Prescriber.

A record of the transaction should be entered in the patient's Prescription Medication Record.

6. Characteristic of Staff

Qualifications
Required

Pharmacist whose name is currently on the practising section of the pharmaceutical register held by The Royal Pharmaceutical Society of Great Britain.

SCHEDULE 1

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Gastro-Intestinal System
Section 1**

Part A: All medicines except those contained in Part B of this Schedule listed in Gastro-Intestinal System, section 1 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Abdominal colic/distension	Fistulas	Pancreatic disorders
Anal fissures	Food allergy	Primary biliary cirrhosis
Bowel colic	Gastrectomy	Proctitis
Conditions requiring gastric acid reduction	Gastritis	Proctosigmoiditis
Constipation	Gastro-oesophageal reflux disease	Pruritus
Crohn's disease	Gastroprotection	Reflux oesophagitis
Cystic fibrosis	Gustatory sweating	Short bowel syndrome
Diarrhoea	Haemorrhoids	Smooth muscle spasm
Dissolution of gall stones	Hepatic encephalopathy	Ulcerative colitis
Diverticular disease	Infant colic	Ulceration including duodenal; gastric; stomal; stress; NSAID associated
Dysmenorrhoea	Inflammatory bowel disease	Wind pain
Dyspepsia	Irritable bowel syndrome	Zollinger – Ellison syndrome
Excessive respiratory secretions	Management of colostomy and ileostomy patients	
Faecal incontinence	Obesity	

Part B: The following medicines listed in Gastro-Intestinal System, section 1 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
1.2	Hyoscine butylbromide injection	Acute use only
1.3	All ¹	Diagnostic use only
1.3.1	Nizatidine injection Ranitidine injection	Acute use only
1.3.5	Esomeprazole injection Omeprazole infusion Omeprazole injection Pantoprazole injection	Acute use only
1.5.3	Ciclosporin Methotrexate injection Adalimumab Infliximab	Acute use only Specialist use only
1.6.5	All	Acute use only
1.7.3	All	Acute use only

¹ All H.pylori tests are excluded, please refer to each individual sub section for all other exclusions.

SCHEDULE 2

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine

Cardiovascular System Section 2

Part A: All medicines except those contained in Part B of this Schedule listed in Cardiovascular System, section 2 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acute coronary syndrome	Hyperlipidaemias	Portal hypertension
Angina	Hypertension	Prevention of MI and stroke
Anxiety	Hyperthyroidism	Primary hyperaldosteronism
Arrhythmias	Hypertriglyceridaemia	Primary pulmonary hypertension
Ascites	Hypertrophic cardiomyopathy	Prophylaxis of embolisation
Cerebrovascular disease	Intermittent claudication	Pulmonary arterial hypertension
Coronary artery disease	Left ventricular dysfunction	Raynaud's syndrome
Coronary heart disease	Menopausal flushing	Renal complications
Diabetic nephropathy	Menorrhagia	Sitosterolaemia
Dyslipidaemia	Migraine prophylaxis	Systemic sclerosis
Essential tremor	Myocardial infarction	Thromboembolic disease
Fibrinolysis	Occlusive arterial disease	Thyrotoxicosis
Heart failure	Oedema	Transient ischaemic attack
Hereditary angioedema	Peripheral vascular disease	
Hypercholesterolaemia	Phaeochromocytoma	

Part B: The following medicines listed in Cardiovascular System, section 2 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
2.1.1	Digoxin injection Digoxin paediatric injection Digoxin-specific antibody fragments	Acute use only
2.1.2	All	Acute use only
2.2.2	Furosemide injection Bumetanide injection	Acute use only
2.2.5	All	Acute use only
2.3.2	Adenosine Amiodarone injection/sterile concentrate Disopyramide injection Flecainide injection Lidocaine	Acute use only

Sub Section	Excluded Drugs	Rationale
2.4	Propranolol injection Atenolol injection Esmolol Labetalol injection Metoprolol injection Sotalol injection	Acute use only
2.5.1	Ambrisentan Diazoxide injection Hydralazine injection Sodium nitroprusside	Specialist use only Acute use only
2.5.2	Clonidine injection	Acute use only
2.5.3	All	Acute use only
2.5.4	Phenoxybenzamine hydrochloride Phentolamine mesilate	Acute use only
2.6.1	Glyceryl trinitrate injection Isosorbide dinitrate injection	Acute use only
2.6.2	Nimodipine Verapamil injection	Acute use only
2.7 + all subsections	All	Acute use only
2.8.1	Heparin Danaparoid Bivalirudin Lepirudin Heparin flushes Epoprostenol Fondaparinux sodium	Specialist use only
2.8.2	Dabigatran etexilate Rivaroxaban	Specialist use only Acute use only
2.8.3	All	Acute use only
2.9	Abciximab Dipyridamole injection Eptifibatide Tirofiban	Specialist use only Diagnostic use only Specialist use only
2.10.2	All	Acute use only
2.11	Tranexamic acid injection All blood products	Acute use only Specialist use only
2.13	All	Acute use only

SCHEDULE 3

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Respiratory System
Section 3**

Part A: All medicines except those contained in Part B of this Schedule listed in Respiratory System, section 3 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic disorders	Cough	Reduction of sputum viscosity
Anaphylactic reactions	Cystic fibrosis	Reversible airways obstruction
Anxiety	Hypoxaemia	Rhinitis
Asthma	Migraine	Urticaria
Bronchial secretion expulsion	Nasal congestion	
Chronic obstructive pulmonary disease	Pruritis	

Part B: The following medicines listed in Respiratory System, section 3 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
3.1.1.1	Salbutamol infusion Salbutamol injection Terbutaline injection	Acute use only
3.1.1.2	Adrenaline injection	Acute use only
3.1.3	Aminophylline injection	Acute use only
3.4.1	Chlorphenamine injection Promethazine injection	Acute use only
3.4.2	All	Specialist use only
3.4.3	All except Anapen and Epipen injections for self administration	Acute use only
3.5 + all subsections	All	Specialist use only
3.7	Erdosteine	Acute use only
3.9.1	Codeine linctus Methadone linctus Morphine HCL linctus	Potential for abuse Controlled drug

SCHEDULE 4

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Central Nervous System
Section 4**

Part A: All medicines except those contained in Part B of this Schedule listed in Central Nervous System, section 4 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Aggressive, violent, dangerously impulsive or self-mutilating behaviour	Febrile convulsion	Nocturnal enuresis
Agitation and restlessness	Generalised anxiety disorder	Obesity
Alcohol dependence	Headache	Obsessive compulsive disorder
Alcohol withdrawal	Hypersalivation	Pain
Anxiety	Infantile spasms	Panic disorders
Attention deficit hyperactivity disorder	Insomnia	Parkinson's disease
Bipolar disorder	Intractable hiccup	Phobic and obsessional states
Bulimia nervosa	Labyrinthine disorders	Post-traumatic stress disorder
Cataplexy associated with narcolepsy	Mania	Psychomotor agitation
Childhood autism	Meniere's disease	Pyrexia
Choreas	Menopausal flushing	Restless legs syndrome
Daytime sleepiness	Migraine	Schizophrenia and other psychoses
Dementia	Motion sickness	Sedation
Depression	Motor neurone disease	Seizures
Deviant antisocial sexual behaviour	Motor tics	Smoking cessation
Drug-induced extra-pyramidal symptoms	Movement disorders	Social anxiety disorder
Dysmenorrhoea	Muscle spasm	Status epilepticus
Dyspepsia & GORD	Myoclonus	Tourette syndrome
Epilepsy	Narcolepsy	Vertigo
Essential tremor	Nausea and vomiting	Vestibular disorders
Excitement	Neuropathic pain	

Part B: The following medicines listed in Central Nervous System, section 4 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
4.1.1	Temazepam Sodium oxybate Melatonin	Controlled drug Specialist use only Acute use only
4.1.2	All injections Meprobamate	Acute use only Controlled drug
4.1.3	All	Controlled drug
4.2.1	All injections Clozapine ²	Acute use only Registration required
4.4	Dexamfetamine Methylphenidate Cocaine	Controlled drug
4.5.2	Diethylpropion Phentermine Rimonabant	Controlled drug Specialist use only
4.6	All injections Aprepitant Nabilone	Acute use only
4.7.1	Paracetamol infusion	Acute use only
4.7.2	All injections Buprenorphine Diamorphine hydrochloride Dipipanone hydrochloride Fentanyl Hydromorphone hydrochloride Methadone hydrochloride Morphine salts ³ Oxycodone hydrochloride Oxycodone hydrochloride with naloxone Pentazocine Pethidine hydrochloride	Acute use only Controlled drug
4.7.4.2	Methysergide	Specialist use only
4.8.1	All injections and infusions Clobazam ⁴ Phenobarbital	Epilepsy only Controlled drug Acute use only
4.8.2	All injections	Acute use only
4.9.3	Botulinum toxin type A and B	Specialist use only
4.10	Buprenorphine Lofexidine hydrochloride Methadone hydrochloride Naltrexone hydrochloride	Controlled drug Acute use only Controlled drug Potential for abuse

² Clozapine can be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that patient.

³ All strengths are not allowed on the PGD including oramorph 10mg/5ml.

⁴ Clobazam can be supplied under the PGD for **epilepsy only and must be endorsed SLS.**

SCHEDULE 5

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Infections
Section 5**

Part A: All medicines except those contained in Part B of this Schedule listed in Infections, section 5 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acne vulgaris	Leprosy	Tuberculosis treatment and chemoprophylaxis
Bacterial infection	Lyme arthritis	Viral infection
Dermatitis herpetiformis	Rheumatic fever	
Fungal infection	Rosacea	

Part B: The following medicines listed in Infections, section 5 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
5.1 + all subsections	All injections and infusions	Acute use only
5.2 + all subsections	All injections and infusions	Acute use only
5.3.1	All	Specialist use only
5.3.2 + all subsections	All infusions	Acute use only
5.3.3	All	Specialist use only
5.3.4	All	Acute use only ⁵
5.3.5	All	Specialist use only
5.4 + all subsections	All	Acute use only
5.5 + all subsections	All	Acute use only

⁵ Refer to emergency planning section for distribution arrangements in the case of pandemic flu.

SCHEDULE 6

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Endocrine System
Section 6**

Part A: All medicines except those contained in Part B of this Schedule listed in Endocrine System, section 6 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acromegaly	Haemophilia	Menstrual disorders
Addison's disease	Hashimoto's thyroiditis	Neuropathic oedema
Adrenocorticol insufficiency	Hereditary angioedema	Nocturia
Amenorrhoea	Hormone replacement therapy	Nocturnal enuresis
Benign fibrocystic breast disease	Hyperprolactinaemia	Osteolytic lesions
Benign prostatic hyperplasia	Hyperthyroidism	Osteoporosis
Blood glucose monitoring	Hypoglycaemia	Pagets disease
Bone metastases (reduction of bone damage)	Hypogonadism	Polycystic ovary syndrome
Breast pain	Hypopituitarism	Postmenopausal symptoms
Cerebral oedema associated with malignancy	Hypothyroidism	Postnatal depression
Congenital adrenal hyperplasia	Inappropriate secretion of antidiuretic hormone	Postponement of menstruation
Diabetes insipidus	Infertility	Premenstrual syndrome
Diabetes mellitus	Inflammatory and allergic disorders	Prolactinoma
Diffuse non-toxic goitre	Insulin-like growth factor-I deficiency	Recurrent miscarriage
Dysfunctional uterine bleeding	Juvenile myxoedema	Thyroid carcinoma
Dysmenorrhoea	Male hypersexuality and sexual deviation	Urinalysis
Endometriosis	Menopausal symptoms	von Willebrand's disease
Galactorrhoea	Menorrhagia	

Part B: The following medicines listed in Endocrine System, section 6 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
6.1.6	Anhydrous glucose	Acute use only
6.2.1	Liothyronine injection	Acute use only
6.2.2	Iodine and iodide	Acute use only
6.3.2	All injections and infusions	Acute use only
6.4.1.1	Estradiol implant	Time period between repeats
6.4.1.2	Progesterone injection	Specialist use only
6.4.2	Testosterone and esters Mesterolone	Controlled drug
6.4.3	All	Controlled drug
6.5.1	All	Specialist use only
6.5.2	Vasopressin Desmopressin injection Terlipressin	Acute use only
6.6.1	Calcitonin injection	Specialist use only
6.6.2	Disodium pamidronate Ibandronic acid injection Ibandronic acid concentrate Zoledronic acid	Specialist use only
6.7.2	All injections	Specialist use only
6.7.3	All	Specialist use only

SCHEDULE 7

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

**BNF/BNFC Class of Medicine Obstetrics, Gynaecology and Urinary Tract Disorders
Section 7**

Part A: All medicines except those contained in Part B of this Schedule listed in Obstetrics, Gynaecology and Urinary Tract Disorders, section 7 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Benign prostatic hyperplasia	Menopausal disorders	Urinary retention
Bladder spasms	Menstrual disorders	Urinary urgency
Contraception	Neurogenic bladder instability	Urological pain
Dysuria	Nocturnal enuresis	Urolithiasis
Enuresis	Postmenopausal symptoms	Vaginal & vulval infections
Erectile dysfunction	Urinary frequency	Vaginal atrophy
Hormone replacement therapy	Urinary incontinence	

Part B: The following medicines listed in Obstetrics, Gynaecology and Urinary Tract Disorders, section 7 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
7.1 + all subsections	All	Specialist use only
7.3.2.2	Etonogestrel implant	Time period between repeats
7.3.2.3	All	Time period between repeats
7.3.4	All	Time period between repeats
7.3.5	All	Acute use only
7.4.4	All	Specialist use only

SCHEDULE 8

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine

Malignant Disease and Immunosuppression Section 8

Part A: All medicines except those contained in Part B of this Schedule listed in Malignant Disease and Immunosuppression, section 8 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anovulatory infertility	Cancer	Nephrotic syndrome
Autoimmune conditions	Graft-versus-host disease	Organ transplantation
Bone-marrow transplantation	Mastalgia	

Part B: The following medicines listed in Malignant Disease and Immunosuppression, section 8 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
8.1 + all subsections	All	Specialist use only
8.2.1	All injections and infusions	Specialist use only
8.2.2	All injections and infusions	Specialist use only
8.2.3	All	Specialist use only
8.2.4	All	Specialist use only
8.3.4.1	Fulvestrant	Specialist use only
8.3.4.2	Buserelin injection Goserelin implant Leuprorelin acetate Triptorelin Degarelix	Specialist use only
8.3.4.3	All	Specialist use only

SCHEDULE 9

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Nutrition and Blood
Section 9**

Part A: All medicines except those contained in Part B of this Schedule listed in Nutrition and Blood, section 9 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anaemias	Iron overload	Prophylaxis of dental caries
Autoimmune hepatitis	Isoniazid neuropathy	Scleroderma
Calcium deficiency	Leber's optic atrophy	Selenium deficiency
Chronic acidotic states	Metabolic disorders	Sickle-cell disease
Cystinuria	Oral nutrition	Sodium depletion
Fluid and electrolyte loss	Peyronie's disease	Thrombocythaemia
Hypercalcaemia	Potassium depletion	Tobacco amblyopia
Hyperparathyroidism	Premenstrual syndrome	Vitamin deficiency states
Hyperphosphataemia	Prevention of methotrexate induced side effects	Wilson's disease
Hypomagnesaemia	Prevention of neural tube defects	Zinc deficiency
Hypophosphataemia	Prophylaxis in chronic haemolytic states	

Part B: The following medicines listed in Nutrition and Blood, section 9 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
9.1.1.2	All	Specialist use only
9.1.2	Folic acid injection	Acute use only
9.1.3	Antilymphocyte globulin Oxymetholone Desferrioxamine mesilate Eculizumab	Specialist use only Controlled drug Specialist use only
9.1.6	All	Specialist use only
9.2.1.1	Polystyrene sulphonate resins	Specialist use only
9.2.2.1	All EXCEPT Water for Injections	Acute use only
9.2.2.2	All	Specialist use only
9.3	All	Specialist use only
9.5.1+ all subsections	All injections and infusions	Acute use only
9.5.2.1	Phosphate intravenous infusion	Acute use only
9.5.4	Zinc sulphate injection	Acute use only

Sub Section	Excluded Drugs	Rationale
9.5.5	Selenium injection	Acute use only
9.6.2	All injections	Acute use only
9.6.3	Ascorbic acid injection	Acute use only
9.6.4	All injections	Acute use only
9.6.6	Phytomenadione injection	Acute use only
9.8.1	Carnitine injection Agalsidase alfa and beta Imiglucerase Galsulfase Idursulfase Laronidase Mercaptamine Alglucosidase alfa Nitisinone Carglumic acid Sodium phenylbutyrate Betaine Miglustat	Specialist use only
9.8.2	All	Acute use only

SCHEDULE 10

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Musculoskeletal and Joint Diseases
Section 10**

Part A: All medicines except those contained in Part B of this Schedule listed in Musculoskeletal and Joint Diseases, section 10 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Ankylosing spondylitis	Leg cramps	Polymyositis
Dermatological conditions aggravated or caused by sunlight	Menorrhagia	Post-herpetic neuralgia
Diabetic neuropathy	Migraine	Prophylaxis of familial mediterranean fever
Dysmenorrhoea	Muscle spasm	Psoriatic arthritis
Gout	Muscle spasticity	Renal stones
Hyperuricaemia	Musculoskeletal disorders	Rheumatic disease
Immunosuppression	Myasthenia gravis	Rheumatoid arthritis
Inflammation	Osteoarthritis	Soft-tissue injury
Juvenile arthritis	Pain	Systemic and discoid lupus erythematosus

Part B: The following medicines listed in Musculoskeletal and Joint Diseases, section 10 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
10.1.1	All injections and infusions	Acute use only
10.1.2.2	All	Specialist use only
10.1.3	All injections and infusions Leflunomide ⁶	Specialist use only Monitoring required ⁶
10.1.4	Probenecid Rasburicase	Specialist use only Acute use only
10.2.1	Neostigmine injection Edrophonium chloride	Acute use only Diagnostic use only
10.2.2	Baclofen intrathecal injection Diazepam injection	Specialist use only Acute use only
10.3.1	All	Acute use only

⁶ Leflunomide can be supplied under the PGD if the patient is within the required monitoring period

SCHEDULE 11

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Eye
Section 11**

Part A: All medicines except those contained in Part B of this Schedule listed in Eye, section 11 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic conjunctivitis	Epilepsy	Ocular hypertension
Anterior uveitis	Glaucoma	Raised intra-ocular pressure
Chronic eye infections	Inflammation	Seasonal keratoconjunctivitis
Corneal ulcers	Miosis	Tear deficiency
Dry eye conditions	Mydriasis	Vernal keratoconjunctivitis

Part B: The following medicines listed in Eye, section 11 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
11.3.2	All	Specialist use only
11.4.1	Loteprednol etabonate	Acute use only
11.5	Tropicamide	Acute use only
11.7	All	Acute use only
11.8.1	Balanced salt solution	Acute use only
11.8.2	Fluorescein sodium Acetylcholine chloride Apraclonidine Pegaptanib Ranibizumab Verteporfin	Specialist use only

SCHEDULE 12

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Ear, Nose and Oropharynx
Section 12**

Part A: All medicines except those contained in Part B of this Schedule listed in Ear, Nose and Oropharynx, section 12 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Chronic otitis media	Nasal staphylococcal eradication	Painful inflammatory conditions of the oropharynx
Denture stomatitis	Oral and perioral infections	Post irradiation mucositis
Dry mouth	Oral and perioral lesions	Rhinitis
Inflammatory conditions of the nose	Oral hygiene	Sjogren's syndrome
Nasal infections	Oral ulceration and inflammation	Symptomatic relief of oral pain
Nasal polyps	Otitis externa (infection or inflammation)	

Part B: The following medicines listed in Ear, Nose and Oropharynx, section 12 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
12.1.1	Aluminium acetate	Acute use only
12.1.3	All	Acute use only
12.2.2	Ephedrine hydrochloride Xylometazoline hydrochloride	Acute use only
12.3.1	Flurbiprofen	Acute use only

SCHEDULE 13

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Skin
Section 13**

Part A: All medicines except those contained in Part B of this Schedule listed in Skin, section 13 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acne vulgaris	Herpes	Psoriasis
Actinic keratosis	Hirsutism	Rosacea
Bacterial and viral infections	Hyperhidrosis	Scalp disorders
Bruising	Hyperkeratotic skin disorders	Skin disfigurement
Chilblains	Ileostomy and colostomy care	Skin disinfection and cleansing
Corns and calluses	Inflamed or damaged skin disorders	Skin protection
Cradle cap	Malodorous fungating tumours	Skin ulcers
Dermatitis	Minor wounds, minor burns and abrasions	Superficial basal cell carcinoma
Dry and eczematous skin disorders	Mottled hyperpigmentation	Superficial thrombophlebitis
Fissures	Nappy rash	Urinary rash
Fistulae	Photosensitivity	Varicose ulcers
Fungal nail infections	Pressure sores	Varicose veins
Fungal skin infections	Pruritic skin conditions	Warts and verrucas

Part B: The following medicines listed in Skin, section 13 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
13.3	Topical local anaesthetics Topical antihistamines	Acute use only
13.5.1	Alitretinoin	Specialist use only
13.5.2	Acitretin	Specialist use only
13.5.3	All injections and infusions	Specialist use only
13.6.2	Isotretinoin	Specialist use only
13.7	Podophyllotoxin	Specialist use only
13.10.1.1	Retapamulin	Acute use only
13.10.4	All	Acute use only
13.10.5	All skin tissue adhesives	Acute use only
13.12	Glycopyrronium bromide	Specialist use only

SCHEDULE 14

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine

Immunological Products and Vaccines Section 14

Part A: All medicines except those contained in Part B of this Schedule listed in Immunological Products and Vaccines, section 14 BNF may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

There are no clinical conditions.

Part B: The following medicines listed in Immunological Products and Vaccines, section 14 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
Chapter 14	All	Specialist use only

SCHEDULE 15

**PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT
PRESCRIBED MEDICINES , APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF
AND BNFC, TO NHS PATIENTS BY PHARMACISTS**

BNF/BNFC Class of Medicine

**Anaesthesia
Section 15**

Part A: All medicines except those contained in Part B of this Schedule listed in Anaesthesia, section 15 BNF may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Local anaesthesia	Pain relief	Postherpetic neuralgia
-------------------	-------------	------------------------

Part B: The following medicines listed in Anaesthesia, section 15 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
15.1 + all subsections	All	Acute use only
15.2	All injections and infusions Lidocaine solution Lidocaine spray Lidocaine with tetracaine plasters Lidocaine with phenylephrine solution Cocaine	Acute use only Controlled drug